8-K: Organon CEO Resigns Amid Sales Probe, Interim Leader Appointed

Organon's CEO Kevin Ali resigned following an investigation into improper wholesaler sales practices, leading to the appointment of Joseph Morrissey as Interim CEO and Carrie Cox as Executive Chair.

Summary

• Kevin Ali resigned as Chief Executive Officer and Board member of Organon & Co. on October 26, 2025, in connection with an investigation into wholesaler sales practices.
• Joseph Morrissey, current Executive Vice President and Head of Manufacturing & Supply, was appointed Interim Chief Executive Officer on October 26, 2025.
• Carrie S. Cox, Chair of the Board, was appointed Executive Chair for an interim period, and Robert Essner was named Lead Independent Director.
• An Audit Committee investigation found that Organon asked certain U.S. wholesalers to purchase greater quantities of Nexplanon than demand in Q4 2022, Q3 & Q4 2024, and Q1, Q2 & Q3 2025.
• The company waived inventory management fee performance metrics for wholesalers to accept these sales, enabling them to receive incentive fees they otherwise wouldn't have.
• These improper sales represented less than 1% of consolidated revenue for the years ended December 31, 2022 or 2024, and less than 2% for relevant quarterly periods.
• Without these practices, consolidated revenue for certain periods would have fallen short of company guidance and/or external expectations.
• The Board determined these practices were improper and certain prior statements were inaccurate or incomplete, but no restatement or revision to previously issued financial statements is required.
• There was no finding that the Chief Financial Officer was aware of the improper sales practices, but the Head of U.S. Commercial & Government Affairs was terminated.
• Management's assessment of internal control over financial reporting (ICFR) in the 2024 Form 10-K and PricewaterhouseCoopers LLP's opinion on ICFR as of December 31, 2024, should no longer be relied upon due to material weaknesses.
• Organon expects to file amended Form 10-K/A for 2024 and Form 10-Q/A for Q1 and Q2 2025 to correct previous ICFR determinations and report on material weaknesses and remediation efforts.

Sentiment

Score: 3

Explanation: The sentiment is significantly negative due to the resignation of the CEO under investigation, the discovery of improper sales practices, and the identification of material weaknesses in internal controls over financial reporting. While no restatement is required and the CFO was not implicated, these are serious governance and operational issues that undermine investor confidence.

Positives

• No restatement or revision to any previously issued financial statements is required, indicating the financial impact of the improper sales was limited.
• The Chief Financial Officer was not found to be aware of the improper wholesaler sales practices.
• The company is taking remedial actions to improve financial controls and address material weaknesses.
• The Board has acted swiftly to address the leadership vacuum and governance issues by appointing interim leadership and forming a search committee for a permanent CEO.

Negatives

• The former CEO, Kevin Ali, resigned due to an investigation into improper wholesaler sales practices.
• The company engaged in improper sales practices for its Nexplanon product, manipulating sales figures to meet guidance and external expectations.
• Management's assessment of internal control over financial reporting (ICFR) as of December 31, 2024, and the auditor's opinion on it, can no longer be relied upon due to identified material weaknesses.
• Certain prior company statements were inaccurate or incomplete regarding sales practices.
• The Head of U.S. Commercial & Government Affairs was terminated in connection with the investigation.

Risks

• The timing and completion of the company's reporting of its third quarter 2025 results and other SEC filings (Form 10-K/A, Form 10-Q/A) are subject to uncertainty.
• The evaluation of material weaknesses in internal control over financial reporting and related remediation efforts are ongoing.
• The timing of the review by, and the conclusions of, the company's independent registered public accounting firm regarding the Audit Committee's internal review and the company's financial statements.
• Potential legal or regulatory actions related to the company's sales practices and previously reported financial results.
• The impact of this announcement on the price of the company's common stock and its relationships with investors, employees, suppliers, wholesalers, and lenders.

Future Outlook

The company intends to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. It also expects to file an amendment to its 2024 Form 10-K and Quarterly Reports on Form 10-Q for Q1 and Q2 2025 to correct previous internal control over financial reporting assessments and report on material weaknesses and remediation efforts. A search for a permanent CEO is underway, and the company plans to host a call and webcast to discuss third-quarter 2025 financial results.

Management Comments

• "We believe Organon's focus on operational execution, especially around our growth pillars, as well as reducing our debt ratios will drive long-term shareholder value." Joseph Morrissey, Interim CEO
• "The Board has confidence in Joe Morrissey's ability to drive operational excellence." Carrie Cox, Executive Chair
• "Carrie's deep experience leading global pharmaceutical businesses, coupled with her extensive Board experience, will complement Joe's skills and make her the right partner to assist Joe in leading the Company forward." Robert Essner, Lead Independent Director
• "We thank both Joe and Carrie for stepping up to lead our Company during this period and believe they have the integrity, skills and experience to continue executing on our strategy to drive Organon's business." Robert Essner, Lead Independent Director

Industry Context

NA

Management Changes

Corporate Governance

Legal Proceedings

• The company faces potential legal or regulatory actions related to its improper sales practices and previously reported financial results, as explicitly mentioned in the forward-looking statements.

Stakeholder Impact

• Shareholders: Potential negative impact on stock price due to CEO resignation, investigation findings, and internal control issues. Uncertainty regarding future financial performance and governance.
• Employees: Potential impact on morale and stability due to leadership changes and termination of a senior executive. Uncertainty about future direction.
• Customers: No direct negative impact mentioned, but potential for reputational damage could indirectly affect relationships.
• Suppliers: Potential impact on relationships due to the company's internal issues and focus on remediation.
• Creditors: Potential impact on relationships and credit terms due to governance concerns and financial reporting reliability issues.

Next Steps

• The Board has formed a Search Committee and is engaging a nationally recognized firm to assist in a search for a permanent CEO.
• The company expects to file an amendment to the 2024 Form 10-K (Form 10-K/A) and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, and June 30, 2025 (Form 10-Q/A).
• The company expects to report on any material weaknesses as of December 31, 2024, as well as any related remediation efforts and corrective disclosures in the Form 10-K/A.
• The company currently intends to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.
• The company plans to host a call and webcast to discuss third quarter 2025 financial results in connection with the filing of its Form 10-Q.

Key Dates

Recommendation

The filing reveals severe governance failures, including improper sales practices to meet financial targets, the resignation of the CEO under investigation, and the identification of material weaknesses in internal controls over financial reporting. The unreliability of previous financial statements' internal control assessments, coupled with the termination of a senior executive, signals a significant breakdown in corporate integrity and oversight. While no restatement of financials is currently required, the systemic issues and leadership upheaval create substantial uncertainty and risk. A seasoned investor would likely view these developments as a strong indicator of underlying operational and ethical problems, warranting a 'strong sell' recommendation until the company demonstrates clear and sustained progress in remediation, restores robust internal controls, and establishes stable, trustworthy leadership.

Keywords

Organon, CEO resignation, wholesaler sales practices, SEC investigation, internal controls, material weaknesses, corporate governance, pharmaceuticals, Nexplanon, financial reporting